Paid Advertisement
For adults with severe hypertriglyceridemia (sHTG; triglycerides ≥500 mg/dL), triglyceride burden—and the risk of acute pancreatitis that comes with it—can persist despite diet and conventional lipid-lowering therapy.1-4
TRYNGOLZA® (olezarsen) is the first and only FDA-approved therapy to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG, as an adjunct to diet.1
Stop by Booth #2802 to:
- Review the efficacy and safety data from the CORE and CORE2 trials1
- Discuss the adjudicated acute pancreatitis findings from the clinical program1
- Walk through the apolipoprotein C-III (apoC-III)–targeted mechanism of action1,5
- Ask about once-monthly subcutaneous dosing via a self-administered autoinjector—and about access and support for your patients1,6
Our medical and field teams are on-site throughout exhibit hours. No appointment needed.
McCormick Place Convention Center · Chicago, IL · November 7–9, 2026 · Booth #2802
INDICATION
TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.
Liver Enzyme Abnormalities
TRYNGOLZA can cause increases in liver enzymes and hepatic fat in adults. Increases in liver enzymes were more frequently reported with the 80 mg dose as compared with the 50 mg dose. Consider liver enzyme testing before TRYNGOLZA initiation or an increase in dosage and when clinically indicated thereafter. If persistent elevations in liver enzymes occur, consider dose interruption and/or dose reduction. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue TRYNGOLZA.
ADVERSE REACTIONS
Most common adverse reactions in patients with sHTG (incidence ≥2% higher than placebo) were injection site reactions and liver enzyme increases.
Please see full Prescribing Information for TRYNGOLZA, also available at TRYNGOLZAHCP.com.
References
1. TRYNGOLZA. Prescribing information. Ionis Pharmaceuticals.
2. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691.
3. Patel SB, Wyne KL, Afreen S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025;31(2):236-262.
4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026:S0735-1097(25)10254-4.
5. Brinton EA, Eckel RH, Gaudet D, et al. Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025;403:119114.
6. Data on file. REF-01291. Ionis Pharmaceuticals; 2024.
©2026 Ionis Pharmaceuticals, Inc. TRYNGOLZA is a registered trademark of Ionis Pharmaceuticals, Inc. All rights reserved.
US-OLZ-2600527 v1.0 09/2026